Cargando…
Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials
Most academic precision oncology programs have been designed to facilitate enrollment of patients in early clinical trials with matched targeted agents. Over the last decade, major changes were seen both in the targetable molecular alteration landscape and in drug development trends. In this article...
Autores principales: | Dienstmann, Rodrigo, Garralda, Elena, Aguilar, Susana, Sala, Gemma, Viaplana, Cristina, Ruiz-Pace, Fiorella, González-Zorelle, Jenifer, Grazia LoGiacco, Deborah, Ogbah, Zighereda, Ramos Masdeu, Laia, Mancuso, Francesco, Fasani, Roberta, Jimenez, Jose, Martinez, Paola, Oaknin, Ana, Saura, Cristina, Oliveira, Mafalda, Balmaña, Judith, Carles, Joan, Macarulla, Teresa, Elez, Elena, Alsina, Maria, Braña, Irene, Felip, Enriqueta, Tabernero, Josep, Rodon, Jordi, Nuciforo, Paolo, Vivancos, Ana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446427/ https://www.ncbi.nlm.nih.gov/pubmed/32923891 http://dx.doi.org/10.1200/PO.19.00398 |
Ejemplares similares
-
Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer
por: Serna, Garazi, et al.
Publicado: (2019) -
Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights
por: Dienstmann, Rodrigo, et al.
Publicado: (2017) -
New clinical trial designs in the era of precision medicine
por: Garralda, Elena, et al.
Publicado: (2019) -
Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer
por: Rodriguez-Freixinos, Victor, et al.
Publicado: (2019) -
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
por: Grasselli, J, et al.
Publicado: (2017)